Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2005The Oncologist

FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets

View Full Paper
Ask AI
Bookmark
Share

Authors

MCMartin H. CohenRockefeller FoundationJJJohn R. JohnsonSanta Barbara Museum of Natural HistoryYCYeh‐Fong ChenUnited States Food and Drug Administration

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Cohen et al. (2005) studied this question.

synapsesocial.com/papers/69d7d451a2a48916bbbedef4https://doi.org/10.1634/theoncologist.10-7-461
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies2001 · 1,002 citations
  2. 2TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer2005 · 1,502 citations
  3. 3The Current Situation: Erlotinib (Tarceva®) and Gefitinib (Iressa®) in Non-Small Cell Lung Cancer2005 · 71 citations
  4. 4The Role of Erlotinib (Tarceva, OSI 774) in the Treatment of Non-Small Cell Lung Cancer2004 · 109 citations
  5. 5EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib2004 · 4,368 citations